Home/Pipeline/Docetaxel Alcohol-free Injection

Docetaxel Alcohol-free Injection

Solid Tumors

MarketActive

Key Facts

Indication

Solid Tumors

Phase

Market

Status

Active

Company

Teikoku Pharma

About Teikoku Pharma

Teikoku Pharma USA, founded in 1999, is a commercial-stage biopharmaceutical company with deep expertise in transdermal drug delivery systems. The company leverages its proprietary Hydrohesive® and Matrix patch technologies to develop non-opioid pain management solutions and treatments for CNS disorders, with a pipeline featuring late-stage assets like TPU-006 for post-surgical pain. With a marketed product generating revenue and a strategic focus on global partnerships and licensing, Teikoku is positioned to address significant unmet needs in pain management and neurology.

View full company profile

Therapeutic Areas

Pain Management CNS Disorders Dermatology Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed